Piper Sandler Issues Positive Forecast for Context Therapeutics (NASDAQ:CNTX) Stock Price

Context Therapeutics (NASDAQ:CNTX) had its price target upped by Piper Sandler from $4.00 to $7.00 in a research note released on Tuesday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Several other equities research analysts have also commented on the company. Wall Street Zen upgraded Context Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research note on Wednesday, January 21st. Lifesci Capital upgraded Context Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd. Finally, JonesTrading initiated coverage on shares of Context Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $6.60.

Context Therapeutics Stock Up 5.3%

Shares of NASDAQ CNTX opened at $3.18 on Tuesday. The stock has a market capitalization of $292.18 million, a PE ratio of -8.37 and a beta of 1.96. The firm has a fifty day moving average of $2.41 and a 200-day moving average of $1.60. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Monday, March 23rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.04). Equities research analysts expect that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at about $43,000. XTX Topco Ltd raised its holdings in shares of Context Therapeutics by 858.8% during the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after buying an additional 91,008 shares during the period. Quadrature Capital Ltd acquired a new position in Context Therapeutics during the 4th quarter worth approximately $68,000. Millennium Management LLC acquired a new position in Context Therapeutics during the 4th quarter worth approximately $3,824,000. Finally, Marshall Wace LLP boosted its holdings in Context Therapeutics by 7,153.7% in the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock worth $3,812,000 after acquiring an additional 2,557,448 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics News Summary

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Multiple brokerages boosted ratings and price targets — Piper Sandler raised its price target to $7 and kept an “overweight” rating, Guggenheim reaffirmed a “buy” with a $5 target, and D. Boral Capital reaffirmed a “buy” with a $9 target. These notes increase upside expectations and likely helped buying interest. Analyst Notes
• Positive Sentiment: Clinical catalysts and cash runway: Context expects Phase 1a interim data for CTIM‑76 (CLDN6 x CD3) in June 2026 and for CT‑95 (MSLN x CD3) in September 2026, with CT‑202 Phase 1 dosing planned in Q3 2026. Management reported $66.0M cash as of 12/31/25, which it says funds operations into mid‑2027 — a near‑term runway that supports continued development. Full-Year 2025 Results
• Neutral Sentiment: Company updated its corporate presentation highlighting the evolving T‑cell engager pipeline; useful for investors but not an immediate price driver by itself. Pipeline Update
• Neutral Sentiment: Short‑interest reports in late March show anomalous “0 shares / NaN” values across multiple feeds — likely a data/reporting error rather than a true change in short interest; treat these entries with caution.
• Negative Sentiment: Quarterly EPS miss: Context reported -$0.14 EPS for the quarter, missing the consensus -$0.10 estimate — a near‑term negative that can weigh on sentiment. Earnings Release / Market Reaction
• Negative Sentiment: Widening losses and lower cash vs. 2024: Net loss increased to $36.1M (from $26.7M) and cash fell to $66.0M from $94.4M a year earlier — increases R&D spend and burn risk, which could pressure the stock if upcoming data or financing plans disappoint. Financials & Milestones

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.